What is Leerink Partnrs' Forecast for Geron FY2024 Earnings?

Geron Co. (NASDAQ:GERN - Free Report) - Leerink Partnrs cut their FY2024 earnings per share estimates for Geron in a research note issued to investors on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings per share of ($0.29) for the year, down from their prior forecast of ($0.28). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q4 2024 earnings at ($0.06) EPS, Q1 2025 earnings at ($0.03) EPS, FY2025 earnings at $0.00 EPS and FY2026 earnings at $0.19 EPS.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the prior year, the business posted ($0.08) EPS. The business's revenue for the quarter was up 17138.4% compared to the same quarter last year.

A number of other analysts have also recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 target price on shares of Geron in a research note on Friday, December 13th. Scotiabank initiated coverage on shares of Geron in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $6.00 price objective for the company. Barclays raised Geron to a "strong-buy" rating in a research report on Friday, November 29th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Geron in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Geron currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.15.

Geron Stock Up 0.6 %

NASDAQ GERN traded up $0.02 during trading on Wednesday, hitting $3.42. The company's stock had a trading volume of 8,038,189 shares, compared to its average volume of 12,254,668. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The company has a market cap of $2.07 billion, a PE ratio of -10.69 and a beta of 0.55. The business's 50 day simple moving average is $3.85 and its 200-day simple moving average is $4.25.

Institutional Investors Weigh In On Geron

A number of large investors have recently modified their holdings of the business. RTW Investments LP acquired a new position in Geron during the third quarter worth about $200,268,000. Darwin Global Management Ltd. purchased a new position in Geron in the 2nd quarter worth approximately $106,185,000. Holocene Advisors LP acquired a new position in shares of Geron during the 3rd quarter worth approximately $82,498,000. Janus Henderson Group PLC grew its position in shares of Geron by 140.0% in the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company's stock valued at $102,193,000 after purchasing an additional 13,163,889 shares in the last quarter. Finally, Farallon Capital Management LLC increased its holdings in shares of Geron by 124.6% in the second quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company's stock valued at $71,389,000 after purchasing an additional 9,342,000 shares during the last quarter. Hedge funds and other institutional investors own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.